Protac – Talk Bio

Pfizer and Arvinas Abandon Commercialization of PROTAC Inhibitor, Triggering Layoffs and Pipeline Refocus

1 month ago talkbio0Tagged Arvinas, CDK inhibitors, layoffs, Malignant neoplasm of breast, Neoplasms, Pfizer, Protac, United States Food and Drug Administration, Vepdegestrant

Pfizer; Arvinas; PROTAC; vepdegestrant; layoffs; out-licensing; FDA; breast cancer; oncology; CDK inhibitors

Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio

2 months ago talkbio0Tagged Autoimmune Diseases, clinical pipeline, Immunoregulation, Inhibitor, investors, Odyssey, Precision - temporal, preclinical programs, Protac, RIPK2, Series D financing, Technology

Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors

Novartis Secures $1B Protein Degrader Deal with Arvinas and Initiates MorphoSys Tender Offer

2 years ago talkbio0Tagged Androgen Receptor Degrader, Arvinas, MorphoSys Tender Offer, Novartis, Protac, Protein Degrader Deal

Novartis, Arvinas, Protein Degrader Deal, PROTAC® Androgen Receptor Degrader, MorphoSys Tender Offer